Healthcare >> CEO Interviews >> June 2, 2003
BRUCE L.A. CARTER has been President and Chief Executive Officer
of ZymoGenetics, Inc., since April 1998 and a Director since
1987. From 1994 to December 1998, Dr. Carter served as Chairman
of the Board of ZymoGenetics and, from 1988 to 1994, served as
President. From 1994 to 2000, Dr. Carter was Corporate Executive
Vice President and Chief Scientific Officer for Novo Nordisk A/S,
the former parent company of ZymoGenetics. Dr. Carter led the
negotiations that established ZymoGenetics as an independent
company from Novo Nordisk in 2000. He joined ZymoGenetics in 1986
as Vice President of Research and Development. From 1982 to 1986,
Dr. Carter held various positions at G.D. Searle & Co., Ltd., a
British pharmaceutical company, including Head, Molecular
Genetics. From 1975 to 1982, he was a Lecturer at Trinity
College, University of Dublin. Dr. Carter received a BSc with
Honors in Botany from the University of Nottingham, England, and
a PhD in Microbiology from Queen Elizabeth College, University of
London. During his college years, Dr. Carter was a member of the
UK Olympic Rowing Team. Dr. Carter currently serves as a Director
of BIO, BioImage, Epigenomics, Skeletech and WBBA. Profile
gone on over the past year or so that investors should focus on?
Dr. Carter: I think we have made considerable progress on
